SCHEMBL14926327

SCHEMBL14926327

CCC(=O)CCCCCOC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
TSHR P16473 4/20 0.41
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 3/20 0.39
NAAA Q02083 1/20 0.39
DGKA P23743 1/20 0.39
HAO1 Q9UJM8 1/20 0.36
CES2 O00748 3/20 0.36
CES1 P23141 3/20 0.36
HTR2C P28335 1/20 0.35
PPARG P37231 4/20 0.34
PPARD Q03181 4/20 0.34
PPARA Q07869 4/20 0.34
GPR84 Q9NQS5 3/20 0.34
HDAC11 Q96DB2 3/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
TLR2 O60603 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15028760 1.00 ALDH1A1 (0.61) ALDH1A1TSHRKMT2AMAPTTDP1
SCHEMBL31522116 0.98 ALDH1A1 (0.58) ALDH1A1TSHRKMT2AMAPTTDP1
SCHEMBL27441223 0.95 ALDH1A1 (0.56) ALDH1A1TSHRKMT2AMAPTTDP1
SCHEMBL7969593 0.91
SCHEMBL30432418 0.88 ALDH1A1 (0.70) ALDH1A1TSHRKMT2AMAPTDGKA
SCHEMBL27441275 0.87 ALDH1A1 (0.48) ALDH1A1GPR84PTPN1FFAR1FFAR4
SCHEMBL27441244 0.86 ALDH1A1 (0.45) ALDH1A1TSHRKMT2AMAPTTDP1
SCHEMBL31220891 0.84 ALDH1A1 (0.59) ALDH1A1TSHRKMT2AMAPTTDP1
SCHEMBL9891378 0.84 ALDH1A1 (0.59) ALDH1A1TSHRKMT2AMAPTTDP1
SCHEMBL9891380 0.84 ALDH1A1 (0.59) ALDH1A1TSHRKMT2AMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-04 US disclosed
US-9340634-B2 Polymer for use in liquid crystal alignment layer DIC CORPORATION (JP) 2016-05-17 US disclosed
US-9340634-B2 Polymer for use in liquid crystal alignment layer DIC CORPORATION (JP) 2016-05-17 US disclosed
US-20130116396-A1 POLYMER FOR USE IN LIQUID CRYSTAL ALIGNMENT LAYER DIC CORPORATION (JP) 2013-05-09 US disclosed
US-20130116396-A1 POLYMER FOR USE IN LIQUID CRYSTAL ALIGNMENT LAYER DIC CORPORATION (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 MAPT, PSEN1, PSEN2 ALDH1A1 3938/4885TSHR 2547/4885KMT2A 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.